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ABSTRACT 26 
Acinetobacter baumannii is a multidrug resistant pathogen associated with hospital outbreaks 27 
of infection across the globe, particularly in the intensive care unit. The ability of 28 
A. baumannii to survive in the hospital environment for long periods is linked to antibiotic 29 
resistance and its capacity to form biofilms. Here we studied the prevalence, expression and 30 
function of the A. baumannii biofilm-associated protein (Bap) in 24 carbapenem-resistant 31 
A. baumannii ST92 strains isolated from a single institution over a 10-year period. The bap 32 
gene was highly prevalent, with 22/24 strains positive for bap by PCR. Partial sequencing of 33 
bap was performed on the index case strain MS1968 and revealed it to be a large and highly 34 
repetitive gene approximately 16 kb in size. Phylogenetic analysis employing a 1,948 amino 35 
acid region corresponding to the C-terminus of Bap showed BapMS1968 clusters with Bap 36 
sequences from clonal complex (CC) 2 strains ACICU, TCDC-AB0715 and 1656-2, and is 37 
distinct from CC1 strains. Using overlapping PCR, the bapMS1968 gene was cloned and its 38 
expression in a recombinant E. coli strain resulted in increased biofilm formation. A Bap-39 
specific antibody was generated and western blot analysis showed the majority of 40 
A. baumannii strains expressed an ~200 kDa Bap protein. Further analysis of three Bap-41 
positive A. baumannii strains demonstrated Bap is expressed at the cell surface and is 42 
associated with biofilm formation. Finally, biofilm formation by these Bap-positive strains 43 
could be inhibited by affinity-purified Bap antibodies, demonstrating the direct contribution 44 
of Bap to biofilm growth by A. baumannii clinical isolates.  45 
 46 
47 
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INTRODUCTION 48 
Acinetobacter baumannii is a Gram-negative bacterial pathogen associated with multidrug 49 
resistance and hospital outbreaks of infection, particularly in the intensive care unit (11). 50 
A. baumannii accounts for almost 80% of all reported Acinetobacter infections, including  51 
ventilator-associated pneumonia, bacteremia, meningitis, peritonitis, urinary tract infections 52 
and wound infections (2, 4). The rapid emergence of multidrug resistant A. baumannii strains 53 
has left limited treatment options for patients, with most strains resistant to clinically useful 54 
antibiotics such as aminoglycosides, fluoroquinolones, β-lactams (including carbapenems), 55 
tetracyclines and trimethoprim-sulfamethoxazole (35, 39). 56 
 57 
In addition to antibiotic resistance, the ability to form biofilms represents an important factor 58 
associated with A. baumannii virulence. Biofilms are sessile bacterial communities enclosed 59 
in a matrix comprised of extracellular material that can include polysaccharide, protein and 60 
DNA (20). Biofilm formation by bacterial pathogens is associated with enhanced tolerance to 61 
host immune defences, disinfectants and antimicrobials (17, 40). A. baumannii strains readily 62 
form biofilms in vitro and some of the molecular mechanisms associated with this phenotype 63 
have been studied; genes associated with biofilm formation include the csu locus (encoding 64 
the chaperone-usher Csu fimbriae), the pga locus (encoding the polysaccharide poly-N-acetyl 65 
glucosamine; PNAG), ompA (encoding the outer membrane protein OmpA) and bap 66 
(encoding the biofilm-associated protein Bap) (6, 13, 18, 19, 31, 33, 48). 67 
 68 
A. baumannii Bap (BapAb) is a cell surface protein associated with biofilm formation. In the 69 
A. baumannii bloodstream isolate 307-0294, BapAb307-0294 is a large 854 kDa protein 70 
comprised of multiple copies of repeat elements (31). Mutation of bap in A. baumannii 307-71 
0294 resulted in decreased biofilm growth and decreased adherence to human bronchial 72 
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epithelial and neonatal keratinocyte cells (3, 31). Bap homologues have also been identified 73 
and characterised in other bacteria, including from other genera typically associated with 74 
hospital-acquired infection such as Staphylococcus (7), Enterococcus (15, 47),  and 75 
Pseudomonas (16, 22). In Staphylococcus aureus, Bap (BapSa) has been well characterised 76 
and is an important virulence factor that contributes to initial attachment, intercellular 77 
adhesion and biofilm maturation (7, 29). Bap proteins from other organisms contribute to 78 
different stages of biofilm formation and adhesion to eukaryotic host cells (7, 29). 79 
 80 
We previously assessed the molecular epidemiology of A. baumannii within a single, large 81 
institution and showed that A. baumannii strains from sequence type 92 (ST92) were 82 
dominant over a 10-year period (39). In this study we have examined the role of Bap in these 83 
A. baumannii ST92 strains. We show that almost all A. baumannii ST92 strains express Bap 84 
and that its expression is strongly associated with biofilm formation. This is the first analysis 85 
of Bap function in A. baumannii ST92 strains associated with hospital infection outbreaks. 86 
 87 
MATERIALS AND METHODS 88 
Bacterial strains, plasmids and growth conditions. Twenty-four carbapenem-resistant 89 
ST92 clinical isolates were selected from a collection of A. baumannii (isolated between 1999 90 
and 2009) that caused sporadic and outbreak cases at the Royal Brisbane and Women’s 91 
Hospital, Brisbane, Australia (Table 1), some of which have been described previously (39). 92 
The following E. coli strains were used: MS2989 (DH10β containing plasmid pSG25; 93 
bapMS1968 in pBR322) and MS3640 (DH10β containing the vector control plasmid pBR322).  94 
A. baumannii strains were routinely grown at 28°C in tryptic soy broth (TSB - Becton, 95 
Dickinson) supplemented with ampicillin (100 µg/ml) or kanamycin (50 µg/ml) as required. 96 
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E. coli strains were cultivated in Luria Bertani (LB) medium supplemented with ampicillin 97 
(100 µg/ml) as required. 98 
 99 
DNA manipulations and genetic techniques. Chromosomal DNA was extracted from 100 
A. baumannii strains according to methods previously described (53). PCR was performed 101 
using either Taq polymerase (New England Biolabs) or Expand Long Template PCR System 102 
(Roche) according to the manufacturer’s instructions. PCR products were purified using 103 
QIAquick PCR Purification Kit or QIAquick Gel Extraction Kit with spin columns according 104 
to manufacturer’s instructions (Qiagen). Standard cloning techniques were employed to 105 
construct recombinant plasmids (41); plasmid DNA was isolated using the QIAprep Spin 106 
Miniprep or Midiprep Kit (Qiagen). DNA sequencing reactions were carried out with the ABI 107 
BigDye Terminator Sequencing Kit (Version 3.1) (Applied Biosystems). 108 
 109 
PCR screening of the bap gene. The 24 ST92 A. baumannii clinical isolates were screened 110 
for the presence of the bap gene using primers 1415F (5'-111 
tacttccaatccaatgctagggagggtaccaatgcag) and 1416R (5'-ttatccacttccaatgatcagcaaccaaaccgctac). 112 
This gene region corresponded to the same region selected for anti-Bap serum production. 113 
 114 
Size determination and cloning of the bap gene. In order to ascertain the exact size of the 115 
MS1968 bap gene, a long range PCR was performed using the Expand Long Template PCR 116 
System 1 (primers 1649F [5'-ctagccaaccatgcatgatccaaat] and 1650R [5'-117 
ggatcctttaaaggttgcggttccag]). Amplification products were then resolved on a low percentage 118 
agarose gel using the Lambda DNA/HindIII marker (Fermentas) as a reference and the 119 
product size was estimated using the Bio-Rad Image Lab software (Bio-Rad). For cloning 120 
bap into pBR322, the bap gene of MS1968 was amplified in two sections: 5' fragment 121 
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(primers 1649F and 1650R) and 3' fragment (1651F [5'-cttggtaggcggagcagtag] and 1652R 122 
[5'-ggatccgcatgaactctttcaaagctagg]). The 5' fragment was digested with BmtI/BamHI and 123 
ligated into the BmtI/BamHI sites of pBR322 to generate plasmid pSG24. Screening primers 124 
1415F and 1416R were used to verify presence of the 5' bap fragment on pSG24, and primers 125 
831F (5'-gcgctcatcgtcatcctc) and 1161R (5'-cccttatgcgactcctgc), which target the plasmid at 126 
the junction sites, were used to verify the co-joining plasmid-insert region by sequencing. 127 
The 3' fragment was digested with BsrGI/BamHI and ligated into the BsrGI/BamHI sites of 128 
pSG24 to generate pSG25. This plasmid was verified by sequencing the 5' and 3' joining 129 
sites. The confirmed clone (MS2989) was then tested for Bap expression and biofilm 130 
formation. 131 
 132 
DNA sequencing, assembly and bioinformatics. The sequence of the bapMS1968 gene in 133 
pSG25 was determined by primer walking and Sanger sequencing and sequence reads were 134 
manually assembled using Vector NTI Advance® software (Life Technologies). The 135 
assembled DNA sequence of bapMS1968 was compared against bapAB307-0294 using Easyfig 136 
(45). The C-terminal sequence of BapMS1968 (1,948 amino acids) was determined using the 137 
BLASTp program (NCBI) and aligned with Bap homologues obtained from the NCBI 138 
database using Vector NTI Advance® and ClustalW2 (27). The alignment generated using 139 
Vector NTI Advance® was used to determine the region within Bap homologues that 140 
corresponded with the C-terminal sequence of BapMS1968. A neighbour-joining tree was 141 
generated using MEGA5 (46) by comparing 1,948 amino acids from the C-terminal sequence 142 
of BapMS1968 against amino acid sequences of Bap homologues identified on the NCBI 143 
database. 144 
 145 
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Generation of Bap polyclonal antiserum, affinity purification and immunoblotting. A 146 
polyclonal antibody against BapMS1968 was prepared by amplifying a 1,254 bp segment of the 147 
bapMS1968 gene using primers 1415F and 1416R with ligation-independent cloning (LIC) 148 
overhangs flanking both ends of the primers to enable cloning into the pMCSG7 6xHistidine 149 
N-terminal tagged expression vector (12). The resultant plasmid (pSG13) contained base 150 
pairs 132-1,386 of bapMS1968 fused to an N-terminal 6xHis-encoding sequence. This bap 151 
sequence corresponds to amino acid residues 45-462 (418 amino acids) of the BapMS1968 152 
sequence. E. coli BL21 was transformed with plasmid pSG13 and correct clones were 153 
confirmed by PCR and sequencing using primers 1508F (5'-taatacgactcactataggg) and 1509R 154 
(5'-tatgctagttattgctcag). MS2788 (BL21+pSG13) was induced with 1 mM isopropyl β-D-1-155 
thiogalactopyranoside (IPTG), and the resultant fusion protein was purified using the Qiagen 156 
Ni-NTA Spin Kit according to the manufacturer’s instructions. Protein purity was assessed 157 
by SDS-PAGE analysis and quantified using a bicinchoninic acid kit (Sigma-Aldrich) (50). A 158 
polyclonal anti-Bap serum was raised in rabbits at the Institute of Medical and Veterinary 159 
Sciences (South Australia). 160 
 161 
Affinity chromatography was employed to purify Bap-specific antibodies from the rabbit 162 
polyclonal anti-Bap serum as follows: A 30 ml culture of MS2788 was grown at 37°C to 163 
OD600nm of 0.6 in the presence of 1 mM IPTG. Cells were pelleted via centrifugation and 164 
resuspended in chilled sonication buffer (25 mM Tris, 150 mM NaCl, pH 7.0). The 165 
suspension was sonicated three times of 30 sec burst each with a two-minute incubation on 166 
ice in between. The cell extract was centrifuged at 12,000 x g for 20 mins at 4°C. The column 167 
was prepared using a 1 ml bed volume of TALON cobalt metal affinity resin (Clontech) and 168 
equilibrated using 5 ml of equilibration/wash buffer (25 mM Tris, 10 mM NaCl, pH 7.0). The 169 
MS2788 cell lysate was applied to the column; and non-specific proteins removed using 170 
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20 ml of equilibration/wash buffer. An aliquot of the polyclonal Bap antiserum was diluted 171 
with an equal volume of TBS buffer (pH 7.2-7.4) and applied to the affinity column. Non-172 
specific proteins were removed using equilibration/wash buffer. Bap-specific antibodies 173 
bound on the column were eluted using a Gentle Ag/Ab Elution Buffer, pH 6.6 (Pierce). A 174 
30 kDa desalting column (Millipore) was used to concentrate and exchange the purified 175 
antibodies into TBS buffer. Flow-throughs were collected at every step during purification 176 
for SDS-PAGE and immunoblotting analysis. Immunoblotting was performed as previously 177 
described (50). A 1:200 dilution of affinity purified Bap-specific antibodies was used as 178 
primary serum and the secondary antibody was alkaline phosphatase-conjugated anti-rabbit 179 
IgG (Sigma-Aldrich). 180 
 181 
Extracellular Matrix (ECM) protein binding assays. ECM protein binding by 182 
A. baumannii to MaxGelTM Human ECM (Sigma-Aldrich) was performed as described 183 
previously with the exception that wells were washed with PBS, quenched with 2% BSA in 184 
PBS for 1 h and overnight bacterial cultures were standardised to OD600 of 1.0 (14). For 185 
negative control wells, PBS was added instead of bacteria. Instead of performing an ELISA 186 
assay, adherent cells were stained with 0.01% crystal violet for 30 mins at room temperature. 187 
Wells were washed twice with PBS and incubated with 200 µl ethanol/acetone (80:20) for 1 h 188 
at room temperature with gentle agitation. Absorbance measurements were obtained at 189 
595 nm and results were analysed by ANOVA (GraphPad Prism 5 software). 190 
 191 
Biofilm study. Biofilm formation by A. baumannii on 96-well polystyrene plates (Iwaki) was 192 
performed as described in previous protocols with the exception that strains were grown at 193 
28°C in TSB under static conditions (42). Biofilm formation by DH10β was performed as 194 
described above with the exception that cells were grown under shaking conditions in 195 
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polyvinylchloride (PVC) microtitre plates containing M9 supplemented with 0.3% casamino 196 
acids. Briefly, strains were grown as shaking cultures at 250 rpm for 20 h at 28°C in the 197 
appropriate culture medium supplemented with antibiotics; then inoculated into microtitre 198 
plates with fresh medium and incubated for 24 h at 28°C; wells were washed to remove 199 
unbound cells and subsequently stained with 0.01% crystal violet. Bound cells were 200 
quantified by addition of ethanol/acetone (80:20) and measurement of the solubilised stain at 201 
an optical density of 595 nm using a SpectraMax 250 microtitre plate reader with SOFTmax 202 
Pro v2.2.1 software (Molecular Devices). Readings obtained were analysed by ANOVA 203 
(GraphPad Prism 5 software). These experiments were performed in eight replicates. 204 
Inhibition of biofilm formation using Bap affinity purified antibody was performed using the 205 
microtitre plate biofilm protocol mentioned for A. baumannii, with the exception that Bap-206 
specifc antibodies were added to a final concentration of 1:10 before addition of bacteria to 207 
the polystyrene plate. Readings obtained were analysed by ANOVA. This experiment was 208 
performed in quadruplicates. Flow chamber biofilm experiments were performed as 209 
previously described (26), with the exception that cells were grown in TSB supplemented 210 
with ampicillin and detected using 0.1 µM BacLightTM green fluorescent stain (Molecular 211 
Probes). Briefly, biofilms were allowed to form on glass surfaces in a multichannel flow 212 
system that permitted online monitoring of community structures. Flow cells were inoculated 213 
with standardised overnight cultures grown in TSB. Biofilm development was monitored by 214 
confocal laser scanning microscopy (CLSM) from 19-48 h post inoculation. This experiment 215 
was performed in duplicates. 216 
 217 
Microscopy and image analysis. An anti-Bap-specific serum was used for 218 
immunofluorescence microscopy as previously described (51) with modifications where 219 
strains were grown in TSB and a 1:5 dilution of the primary antibody was used followed by 220 
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goat anti-rabbit IgG antibody conjugated to FITC (1:500) as the secondary antibody. 221 
Microscopic observation of biofilms and image acquisition was performed on a confocal laser 222 
scanning microscope (LSM510 META, Zeiss). Vertical cross sections through the biofilms 223 
were visualised using the Zeiss LSM image examiner and the z-stacks were analysed using 224 
COMSTAT software (21). Results obtained were analysed by ANOVA (Minitab® Statistical 225 
Software). Images were further processed for display by using Photoshop software (Adobe 226 
Systems Incorporated). 227 
 228 
RESULTS 229 
The bap gene is highly prevalent in A. baumannii ST92 strains. Twenty four carbapenem 230 
resistant A. baumannii ST92 strains isolated from a single institution during a 10-year period 231 
from 1999 to 2009 were examined for the presence of the bap gene. Initially, a draft genome 232 
sequence of one strain, MS1968, was determined and this provided a partial sequence for 233 
bap, albeit with gaps in the large repeat regions. Based on this sequence primers 1415F and 234 
1416R were designed to amplify a 1,225 bp segment of bapMS1968 from a non-repetitive 235 
region. PCR analysis was performed on all 24 A. baumannii ST92 strains and a product of the 236 
correct size was detected in 91.7% (22/24) of the strains, demonstrating that the bap gene is 237 
highly prevalent in our collection (Table 1). 238 
 239 
Cloning of the bap gene from A. baumannii MS1968. Based on the draft genome sequence 240 
of A. baumannii MS1968 and preliminary PCR assays, the size of bapMS1968 was estimated to 241 
be approximately 16 kb (data not shown). In order to clone bapMS1968, two overlapping PCR 242 
amplicons were generated (a 12,144 bp fragment containing the 5' region and a 4,170 bp 243 
fragment containing the 3' region). These fragments were cloned into plasmid pBR322 in a 244 
two-step process to generate plasmid pSG25, which contained the full length bapMS1968 gene.  245 
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 246 
Sequencing of the bapMS1968 gene and comparative analysis with other bap genes. In 247 
order to close the gap within the bapMS1968 gene from the draft genome sequence, the 248 
sequence of bapMS1968 was determined from plasmid pSG25 using a primer walking strategy. 249 
Approximately 9.5 kb of bapMS1968, including 3,783 bp of the 5' region and 5,847 bp of the 3' 250 
region was sequenced, leaving an estimated 5,500 bp gap that could not be closed by this 251 
method (Fig. 1). A nucleotide sequence alignment using ClustalW2 indicated that bapMS1968 252 
and bapAB307-0294 share approximately 50% sequence identity (Fig. 1). The ~5,500 bp 253 
unsequenced region of bapMS1968 is most likely made up of the core repeat module D, thus 254 
causing the eventual sequencing problems. 255 
 256 
Analysis of the 5,847 bp segment corresponding to the 3' region of bapMS1968 revealed an in-257 
frame translated sequence comprising 1,948 amino acids. An amino acid sequence alignment 258 
using ClustalW2 indicated that this region of BapMS1968 shares 37% sequence identity with 259 
the corresponding region of BapAB307-0294 (residues 6,669 to 8,620). The amino acid sequence 260 
similarity of BapMS1968 with other Bap proteins was evaluated using MEGA5 (46). Fig. 2 261 
illustrates a neighbour-joining tree constructed using aligned Bap amino acid sequences from 262 
26 bacterial strains. A consensus tree of 1,000 bootstrap replicates revealed two major clades. 263 
The two clades separate the majority of the Gram-negative and Gram-positive Bap proteins 264 
(with the exception of B. bronchiseptica, P. fluorescens and P. putida). The predicted Bap 265 
protein homologues of A. baumannii cluster within the large clade of the Gram-negative Bap 266 
homologues. A scheme for classifying A. baumannii into clonal complexes (CC) was 267 
proposed by Diancourt et al. in 2010 and reported AB307-0294, AB0057 and AYE as 268 
representatives of CC1, whereas European Clone II isolates ACICU, TCDC-AB0715 and 269 
1656-2 represented CC2 (5, 10, 24). Consistent with this scheme, BapMS1968 clustered 270 
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together with Bap from other CC2 strains. The separate clustering of CC1 and CC2 Bap 271 
proteins indicates the presence of Bap variants within A. baumannii. 272 
 273 
We also examined the genetic context of bap in A. baumannii. Based on the draft genome 274 
sequence of MS1968, the chromosomal location of bap1968 is identical to that previously 275 
described for A. baumannii 307-0294 (1). The bap gene appears to be disrupted in many 276 
complete A. baumannii genome sequences available in public databases, a consequence of its 277 
intrinsic repetitive features that might be an obstacle for the correct assembly of its coding 278 
region. We selected the complete genome sequences of Acinetobacter species in which bap 279 
appeared to be correctly assembled and compared the corresponding genomic regions (Fig. 280 
3A). Bap from AB307-0294 is 94.7% identical at the amino acid level to Bap from AYE and 281 
BJAB0715, however this is reduced significantly when compared to Bap from PHEA-2 282 
(67.9% amino acid identity), Bap from ADP1 (28.5% amino acid identity) and Bap from SDF 283 
(27.6% amino acid identity). Despite these differences, bap is located at the same genome 284 
position in all six strains, flanked by a core and a variable region. The core upstream region is 285 
represented by genes encoding succinyl coenzyme synthetase (sucCD), a tricarboxylic cycle 286 
enzyme that catalyses the interconversion of succinyl-CoA and succinate, accompanied by 287 
the production or hydrolysis of GTP (34). The core downstream region contains genes 288 
encoding carbamoylphosphate synthetase (carAB), an intermediate in the biosynthesis of 289 
arginine and pyrimidines (36), and greA, a transcriptional elongation factor with chaperone 290 
activity that inhibits aggregation of proteins under heat shock conditions and promotes the 291 
refolding of denatured proteins (30). The variable flanking region of bap was not conserved 292 
in the Acinetobacter genomes analysed, and contained genes encoding hypothetical proteins, 293 
a gene encoding a putative Na+/H+ antiporter (ABBFA_000774) and genes encoding putative 294 
metalloproteases (ABBFA_000773 and ABBFA_000781). Finally, analysis of the intergenic 295 
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regions up- and downstream of bap revealed the presence of palindromic repeats (Fig. 3B), 296 
suggesting that the variable regions may have been acquired through independent 297 
recombination events. 298 
 299 
Expression of Bap by E. coli harbouring pSG25 results in increased biofilm formation. 300 
To demonstrate functional expression of Bap from plasmid pSG25 in E. coli, a polyclonal 301 
antibody was generated against a conserved, non-repetitive region within BapMS1968. SDS-302 
PAGE and western blot analysis on whole cell lysates of MS2989 (E. coli DH10β containing 303 
pSG25) grown in LB broth identified a ~200 kDa protein that reacted with the Bap-specific 304 
antiserum (data not shown). A microtitre plate biofilm assay demonstrated expression of the 305 
bap gene by DH10β resulted in significantly increased biofilm formation by MS2989 306 
compared to the vector control strain (MS3640) (Fig. 4). Thus, Bap can be expressed by E. 307 
coli and its expression leads to increased biofilm formation. 308 
 309 
Bap is expressed by most A. baumannii ST92 isolates. To investigate the expression of Bap 310 
in our collection of 24 A. baumannii ST92 strains, whole cell lysates were prepared from 311 
each strain following overnight shaking growth in TSB and examined by western blot 312 
analysis using the Bap-specific antibody described above. A strong Bap-specific cross-313 
reacting band was detected at ~200 kDa in all but one of the 24 strains tested (95.8%; Table 314 
1). This analysis identified inconsistencies with respect to the PCR prevalence assay; strains 315 
MS1976 and MS3003 expressed Bap but were negative in the PCR screen for the bap gene, 316 
while MS3007 failed to express Bap but was positve in the PCR screen. Out of the 24 ST92 317 
strains, four strains were selected for further analysis of Bap expression and function, three 318 
strains positive for Bap expression (MS3009, MS3011 and MS3014) and one strain negative 319 
for Bap expression (MS3007) (Fig. 5A).  320 
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 321 
Bap is located at the cell surface. The cellular localisation of Bap in A. baumannii ST92 322 
strains was investigated by immunofluorescence microscopy employing our affinity purified 323 
Bap antibody. Consistent with the western blot analysis (Fig. 5A), the Bap antiserum reacted 324 
with MS3009, MS3011 and MS3014. In contrast, no reaction was observed for MS3007 (Fig. 325 
5B). Thus, Bap is effectively expressed and is localised on the cell surface of A. baumannii 326 
strains MS3009, MS3011 and MS3014.  327 
 328 
BapAb does not mediate binding to ECM molecules. The four strains selected for Bap 329 
characterisation (MS3007, MS3009, MS3011 and MS3014) were tested for their ability to 330 
bind MaxGelTM, a commercially available mixture of human ECM components including 331 
collagens, laminin, fibronectin, tenascin, elastin, a number of proteoglycans and 332 
glycosaminoglycans. None of the strains displayed significant binding to MaxGelTM in this 333 
assay (data not shown), suggesting that Bap expression by MS3009, MS3011 and MS3014 334 
does not lead to adherence to ECM components under the conditions used in this experiment. 335 
 336 
Expression of Bap is associated with strong biofilm formation. Biofilm formation by 337 
A. baumannii was examined using dynamic and static biofilm assays. The continuous flow 338 
chamber method was used to test the ability of Bap to promote biofilm formation in dynamic 339 
conditions, which permits monitoring of the bacterial distribution within an evolving biofilm 340 
at the single cell level using scanning confocal laser microscopy. In this assay, the Bap-341 
positive strains MS3009, MS3011 and MS3014 formed a dense, mat-like biofilm across the 342 
glass surface with significantly higher substratum coverage (53.26%, 60.7% and 60.38%, 343 
respectively) compared to the Bap-negative strain MS3007 (29.96%) (P=0.002; Fig. 6). In 344 
the static microtitre plate assay, the Bap-positive strains MS3009, MS3011 and MS3014 345 
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produced a strong biofilm compared to the Bap-negative strain MS3007 (P<0.0001; Fig. 7). 346 
Taken together, these results demonstrate that the Bap-expressing A. baumannii strains 347 
MS3009, MS3011 and MS3014 can form strong biofilms, while MS3007, which does not 348 
express Bap, does not form a significant biofilm. 349 
 350 
Bap is required for biofilm formation in vitro. To further characterise the role of Bap in 351 
biofilm formation by A. baumannii MS3009, MS3011 and MS3014, we performed microtitre 352 
plate biofilm assays in the presence of affinity purified Bap specific antibody. In these assays, 353 
the addition of 1:10 diluted Bap antibody inhibited biofilm formation by all three strains 354 
(P<0.0001; Fig. 7). These results provide compelling evidence to demonstrate that Bap plays 355 
an important role in biofilm formation by A. baumannii ST92 strains associated with hospital 356 
infection outbreaks. 357 
 358 
DISCUSSION 359 
A. baumannii strains from ST92 and the associated CC92 (also known as European Clone 2 360 
or Worldwide Clone 2) represent the most sampled and widespread A. baumannii sequence 361 
type across the globe. Antibiotic susceptibility within ST92 is variable, suggesting a role for 362 
mechanisms other than antibiotic resistance in its successful dissemination. In this study, we 363 
examined the prevalence, sequence and function of Bap from a collection of A. baumannii 364 
ST92 strains isolated from a single institution over a 10-year period. 365 
 366 
Bap was first described in S. aureus strains that cause bovine mastitis (8). Subsequently, 367 
more Bap homologues have been identified and characterised from a range of Gram-positive 368 
and Gram-negative bacteria, including A. baumannii (7, 9, 15, 16, 22, 23, 25, 28, 29, 31, 38, 369 
43, 44, 47, 49, 52). Common features of Bap in all of these organisms include its large size, 370 
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the presence of multiple tandem repeats, its cell surface location and its role in biofilm 371 
formation. In Pseudomonas fluorescens, a large repeat Bap-like protein referred to as LapA 372 
contributes to surface attachment and biofilm formation (22). LapA is translocated to the cell 373 
surface by an ABC transporter encoded by the adjacent lapEBC genes (32). Similarly, in 374 
Salmonella enterica serovar Enteritidis, BapA is secreted by a type I protein secretion system 375 
(BapBCD) situated downstream of the bapA gene (28). Examination of the genetic location 376 
of bap in A. baumannii did not reveal any evidence of a system that could mediate its 377 
translocation. Thus, the mechanism by which Bap is transported to the surface of A. 378 
baumannii remains to be elucidated. We note that a small but significant increase in biofilm 379 
formation was observed in the recombinant E. coli MS2989 strain expressing Bap, indicating 380 
that there may be some level of redundancy in its mode of export. However, we were unable 381 
to definitively detect Bap expression on the surface of E. coli MS2989 by 382 
immunofluorescence microscopy, suggesting that the level of Bap was very low. 383 
 384 
Our analysis revealed that the bap gene is highly prevalent in A. baumannii ST92 strains. All 385 
but one A. baumannii strain in our collection (i.e. MS3007) also expressed the Bap protein. 386 
The inconsistencies between gene prevalence by PCR and protein expression are most likely 387 
due to sequence variation. It is possible that MS3007 harbours an incomplete or truncated 388 
bap gene. Indeed, Loehfelm et al. previously reported the presence of short homologous 389 
regions of bapAB307-0294 within the genome sequence of A. baylyi and A. baumannii ATCC 390 
17978 (31). 391 
 392 
The previously characterised A. baumannii BapAB307-0294 is a 854 kDa high-molecular-weight 393 
protein consisting of multiple repeat regions (31). In contrast, the A. baumannii ST92 strains 394 
examined in this study all expressed a Bap protein of approximately 200 kDa. A partial 395 
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sequence of the bap gene was obtained from one strain, MS1968, which represented the 396 
index case isolate from a small outbreak in 2001. Given that the A. baumannii MS1968 bap 397 
gene is ~16 kb, we expected it to encode a significantly larger sized protein. It is possible that 398 
Bap1968 is degraded or even processed, however this remains to be determined. The difference 399 
in the size of the bap gene from A. baumannii strains MS1968 (~16 kb) and AB307-0294 400 
(25.863 kb), despite their similar genetic context, also demonstrates there is significant 401 
variation in the bap gene from different A. baumannii strains. The A. baumannii Bap protein 402 
contains a modular structure (37), and the presence of large, identical repeat sequences within 403 
module D of bapMS1968 prevented us from generating a complete sequence of the gene. 404 
However, we did identify a non-repetitive sequence that was used to examine the phylogeny 405 
of Bap from several species. In comparison to BapAB307-0294 (which clustered in CC1), 406 
BapMS1968 clustered in CC2. The two Bap sequences exhibited significant variation and 407 
displayed only 37% amino acid identity over this region. Further analysis of Bap from other 408 
CC1 and CC2 strains was consistent with this clustering, and suggests that the non-repetitive 409 
sequence of Bap can differentiate between CC1 and CC2 strains. When analysed in the 410 
context of Bap sequences from different organisms, all of the A. baumannii Bap homologues 411 
clustered uniquely. It remains to be determined if this non-repetitive region of Bap is 412 
representative of its phylogenic distribution in comparison to the entire protein sequence. 413 
However, given the size and highly repetitive nature of Bap, this approach avoided the 414 
comparative analysis of regions that might potentially contain multiple sequence errors.  415 
 416 
Several lines of evidence suggest that Bap contributes to biofilm formation by A. baumannii 417 
ST92. First, Bap expression by three A. baumannii strains was associated with strong biofilm 418 
growth, while the A. baumannii ST92 strain MS3007, which did not express Bap, did not 419 
form a biofilm in microtitre plate- and flow cell-based assays. Additionally, affinity purified 420 
18 
 
Bap-specific antibodies blocked Bap-mediated biofilm formation by A. baumannii strains 421 
MS3009, MS3011 and MS3014. Taken together, our results demonstrate a role for Bap in 422 
biofilm formation that is consistent with previous literature examining other A. baumannii 423 
strains (3, 31). Our results should provide the basis for more detailed studies to examine the 424 
translocation and function of Bap in A. baumannii, including other common multidrug 425 
resistant sequence types associated with hospital infection outbreaks. 426 
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FIGURE LEGENDS 620 
FIG 1. Physical representation of the nucleotide sequence alignment between bapMS1968 (this 621 
study) and bapAB307-0294 (EU117203) (31). The size of bapMS1968 was determined by PCR 622 
(~16 kb) and the sequence obtained by primer walking. The position of the black (5,500 bp) 623 
scale bar indicates the region that could not be sequenced using primer walking. The yellow 624 
arrow indicates the region (1,254 bp) cloned and expressed for antibody production. The 625 
magenta bar indicates the region (5,847 bp) selected for phylogenetic analysis (Figure 3). 626 
This figure was generated using Easyfig (http://easyfig.sourceforge.net/) with nucleotide 627 
sequence comparison (BLASTn) (45). The level of nucleotide identity is shown in the 628 
gradient scale. 629 
 630 
FIG 2. Neighbour-joining tree indicating sequence similarity of BapMS1968 in relation to Bap 631 
homologues from A. baumannii strains (TCDC-AB0715 [Accession number ADX9358]; 632 
ACICU [ACC58250, ACC58252 to ACC58258]; 1656-2 [ADX04628 to ADX04634]; 633 
ATCC19606 [EEX02997]; ATCC17978 [ABO13109]; AB307-0294 [ABX00640]; AYE 634 
[CAM85746]; AB0057 [ACJ41698]), A. baylyi (CAG69594), Burkholderia cepacia 635 
(AAT36485), Salmonella Enteritidis (ABX46037), Salmonella Typhi (NP_806354), Vibrio 636 
parahaemolyticus (NP_800463), Escherichia coli (ACB16711), Listeria monocytogenes 637 
(CAC98514), Staphylococcus aureus (AAK38834), Staphylococcus epidermidis (AAY28519 638 
and AAK29746 [Bhp]), Bordetella bronchiseptica (AAG53941), Pseudomonas fluorescens 639 
(AAY95545), Pseudomonas putida (NP_742337), Enterococcus faecalis (AAD09858), 640 
Enterococcus faecium (EFF33494), Lactobacillus reuteri (EDX43426) and Streptococcus 641 
pyogenes (AAD39085). Sequences were aligned using ClustalW2 and the phylogenetic tree 642 
was generated in MEGA5 by comparing 1,948 amino acids from the C-terminal sequence of 643 
BapMS1968. Numbers at the branches indicate confidence values determined from 1,000 644 
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bootstrap replications. The A. baumannii Bap proteins cluster according to their CC 645 
designation; a CC has not been proposed for the ATCC strains. The red arrow indicates the 646 
most recent common ancestor shared by CC1 and CC2 Bap proteins. The two major clades 647 
demonstrate separate clustering of Gram-negative and Gram-positive Bap homologues (with 648 
the exception of L. monocytogenes and V. parahaemolyticus).  649 
 650 
FIG 3. Genome context of the bap gene in Acinetobacter. (A) Genomic analysis of different 651 
Acinetobacter species indicates that bap is located at the same chromosomal position in all 652 
strains examined. The genome orientation was reversed for some strains to facilitate 653 
visualisation [indicated by a (-) symbol]. Also indicated are the respective core (black) and 654 
variable (green) regions flanking the bap gene. Orange triangles indicate the localisation of 655 
sequence repeats. Genome alignments were performed using Easyfig (45). (B) Alignment of 656 
palindromic repeats localised upstream and downstream of the bap gene in Acinetobacter. 657 
The axis is indicated by a grey arrow. 658 
 659 
FIG 4. Microtitre plate biofilm formation by MS2989 in comparison to MS3640. Strains 660 
were grown under shaking conditions at 28°C for 24 h in PVC microtitre plates containing 661 
M9 supplemented with 0.3% casamino acids. Plates were washed to remove non-adherent 662 
cells and stained with 0.01% crystal violet. Biofilm formation was quantified by solubilising 663 
the crystal violet stain retained by adhered cells with ethanol/acetone (80:20) and measuring 664 
the absorbance at 595 nm. Results are presented as the mean of eight replicates per strain (± 665 
standard deviation). Mean values of MS3640 (0.4604) and MS2989 (0.7425) were calculated 666 
using GraphPad Prism 5 software (P<0.001). 667 
 668 
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FIG 5. (A) Western blot using Bap-specific antiserum showing expression of Bap (~200 669 
kDa) in A. baumannii MS3009 (lane 3), MS3011 (lane 4) and MS3014 (lane 5) but not 670 
MS3007 (lane 2) from whole cell lysates of overnight shaking cultures. Molecular size 671 
markers (HiMark pre-stained protein standard) are indicated in lane 1. (B) 672 
Immunofluorescence microscopy demonstrating surface localisation of Bap. (i) Phase 673 
contrast and (ii) fluorescence images of MS3007, MS3009, MS3011 and MS3014 cells 674 
following overnight growth with agitation at 28°C. The white bar represents 5 µm. 675 
 676 
FIG 6. Flow chamber biofilm formation by (A) MS3007, (B) MS3009, (C) MS3011 and (D) 677 
MS3014. Biofilm development was monitored by CLSM 48 h post inoculation. Substratum 678 
coverage of each strain is as follows: MS3007=29.96%, MS3009=53.26%, MS3011=60.7% 679 
and MS3014=60.38% (P=0.002). Micrographs represent horizontal sections. Depicted to the 680 
right and below of each individual panel represents the yz plane and xz plane, respectively at 681 
the positions indicated by the lines. 682 
 683 
FIG 7. Microtitre plate assay by MS3009, MS3011 and MS3014. Biofilm inhibition was 684 
performed by supplementing respective wells with a 1:10 dilution of affinity purified Bap 685 
antibodies in TSB to access inhibitory effects on biofilm formation. Plates were incubated 686 
under static conditions at 28°C for 24 h then washed to remove non-adherent cells and 687 
subsequently stained with 0.01% crystal violet. Biofilm formation was quantified by 688 
solubilising the crystal violet stain retained by adhered cells with ethanol/acetone (80:20) and 689 
measuring the absorbance at 595 nm. Results are presented as the mean of quadruplicates per 690 
strain (± standard deviation).  691 
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Table 1. Prevalence and expression of bap in A. baumannii ST92 clinical isolates. 692 
Isolate bap genea Bap expressionb Year of isolation Previous designationc 
MS1962 + + 2004 Q11 
MS1966 + + 2001 Q5 
MS1968 + + 2001 Q6 
MS1970 + + 2001 Q7 
MS1972 + + 2000 - 
MS1976 - + 2000 - 
MS1978 + + 2000 - 
MS1980 + + 2004 Q10 
MS1984 + + 2006 Q15 
MS2992 + + 2005 Q12 
MS2993 + + 2006 Q13 
MS2995 + + 2006 Q16 
MS2996 + + 2006 Q17 
MS2998 + + 2006 Q19 
MS3000 + + 2006 Q21 
MS3002 + + 2007 - 
MS3003 - + 2007 - 
MS3004 + + 2008 Q25 
MS3005 + + 2008 Q26 
MS3007 + - 2008 Q28 
MS3009 + + 2008 - 
MS3010 + + 2008 - 
MS3011 + + 2009 - 
MS3014 + + 2009 - 
aDetermined by PCR. bDetermined by western blot analysis. cRefers to previous strain 693 
designation reported in (33).  694 
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